Cargando…

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment

Three men (aged 64, 65, and 67 years) with advanced lung cancer who had been treated with nivolumab developed interstitial lung disease (ILD) during chemotherapy with docetaxel and ramucirumab. The treatment was clinically effective; however, the patients experienced immune‐related adverse effects d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okeya, Komugi, Kawagishi, Yukio, Yamoto, Mako, Shimizu, Mami, Imizuda, Toshihide, Tsuji, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2020
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176744/ https://www.ncbi.nlm.nih.gov/pubmed/32337046 http://dx.doi.org/10.1002/rcr2.564

Ejemplares similares

Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy
por: Okeya, Komugi, et al.
Publicado: (2019)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Docetaxel‐induced interstitial lung disease among patients with breast cancer: a case series and review of literature
por: Hettiarachchi, Sanjeewa Malinda, et al.
Publicado: (2021)

Urticaria‐like decompression illness in a caisson worker treated successfully in a monoplace chamber
por: Okeya, Komugi, et al.
Publicado: (2022)

Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2023)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)

Sex and gender in interstitial lung diseases
por: Kawano-Dourado, Leticia, et al.
Publicado: (2021)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Interstitial lung disease in lysosomal storage disorders
por: Borie, Raphaël, et al.
Publicado: (2021)

Diagnostic workup of childhood interstitial lung disease
por: Nathan, Nadia, et al.
Publicado: (2023)

Unclassifiable interstitial lung disease: a pathologist's perspective
por: Jones, Kirk D.
Publicado: (2018)

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
por: Sakaguchi, Tadashi, et al.
Publicado: (2020)

Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency
por: Gille, Thomas, et al.
Publicado: (2021)

Exertional dyspnoea in interstitial lung diseases: the clinical utility of cardiopulmonary exercise testing
por: Bonini, Matteo, et al.
Publicado: (2017)

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report
por: Gollard, Russell, et al.
Publicado: (2023)

Hermansky–Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease
por: Yokoyama, Tadafumi, et al.
Publicado: (2021)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
por: Ellis-Caleo, Tim, et al.
Publicado: (2021)

Transbronchial lung cryobiopsy in smoking-related interstitial lung diseases
por: Barata, Margarida, et al.
Publicado: (2020)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer
por: Hata, Akito, et al.
Publicado: (2018)

Granulomatous-Lymphocytic Interstitial Lung Disease Mimicking Sarcoidosis
por: Perlman, David M, et al.
Publicado: (2021)

The role of macrophages in interstitial lung diseases: Number 3 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Rossi, Giulio, et al.
Publicado: (2017)

Multidisciplinary evaluation of interstitial lung diseases: current insights: Number 1 in the Series “Radiology” Edited by Nicola Sverzellati and Sujal Desai
por: Walsh, Simon L.F.
Publicado: (2017)

Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
por: Kokosi, Maria A., et al.
Publicado: (2018)

Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy
por: Ogawara, Daiki, et al.
Publicado: (2017)

Acute hypercapnic respiratory failure in patients with obesity hypoventilation syndrome during the COVID‐19 pandemic: Four case reports
por: Nakamura, Sato, et al.
Publicado: (2023)

Docetaxel-related interstitial pneumonitis
por: Wang, Chung-Jen, et al.
Publicado: (2015)

Concurrence of nivolumab‐induced interstitial lung disease and cancer invasion
por: Kanai, Osamu, et al.
Publicado: (2017)

Exogenous lipoid pneumonia: an important cause of interstitial lung disease in infants
por: Marangu, Diana, et al.
Publicado: (2018)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Computed tomography imaging findings of nivolumab-induced thyroid dysfunction
por: Oki, Tatsuya, et al.
Publicado: (2022)

Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia
por: Koyama, Nobuyuki, et al.
Publicado: (2018)

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
por: Matsumoto, Kinnosuke, et al.
Publicado: (2021)

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
por: Garon, Edward B., et al.
Publicado: (2023)

Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in classical Hodgkin’s lymphoma: report on three cases and literature review
por: Romero, Samuel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fo03943sh45i9olu3agdm5s194